The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2018 | Telomere dysfunction to predict clinical outcomes in CLL
Chris Fegan, MB, MD, FRCP, FRCPath, from Cardiff University, Cardiff, UK, touches on several of the national and international cohort studies he has been involved in, proposing that telomere length is a prognostic factor in chronic lymphocytic leukemia (CLL). The studies have all identified the association between long telomere length and a better clinical outcome for patients. Moving forward, Dr Fegan suggests the use of telomere length to inform patients better on what is likely to happen to them, as it iss the only prognostic marker that is present at diagnosis This interview was recorded at the British Society for Hematology (BSH) 2018 Annual Scientific Meeting, Liverpool, UK.
